Shionogi’s Naldemedine Gains Approval in China for Opioid-Induced Constipation

An announcement from Shionogi & Co ( (JP:4507) ) is now available.

Shionogi & Co., Ltd. announced the acceptance of its New Drug Application for naldemedine, a treatment for opioid-induced constipation, in China. This approval is expected to enhance pain management options in China, where current treatments are limited, and improve the quality of life for patients. The drug, already available in several regions, demonstrated significant efficacy in a Phase III trial in China. Following approval, Shionogi China Co., Ltd. will handle sales through an exclusive agreement with Chia Tai Tianqing Pharmaceutical Group Co., Ltd., potentially boosting Shionogi’s market presence and revenue in China.

The most recent analyst rating on (JP:4507) stock is a Buy with a Yen3100.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.

More about Shionogi & Co

Shionogi & Co., Ltd. is a pharmaceutical company based in Osaka, Japan, specializing in the development of treatments for various medical conditions. The company focuses on improving the quality of life for patients through innovative therapies, including those for opioid-induced constipation, cancer pain management, and other health challenges.

Average Trading Volume: 2,611,915

Technical Sentiment Signal: Strong Buy

Current Market Cap: Yen2100.8B

For detailed information about 4507 stock, go to TipRanks’ Stock Analysis page.